Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study

BACKGROUND: TAS-102 (trifluridine and tipiracil hydrochloride; a novel combination oral nucleoside anti-tumor agent) has recently received regulatory approval for patients with refractory metastatic colorectal cancer (mCRC). Internal review of data at a single-institution showed a trend towards bett...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:BMC Cancer
Main Authors: Kasi, Pashtoon M., Kotani, Daisuke, Cecchini, Michael, Shitara, Kohei, Ohtsu, Atsushi, Ramanathan, Ramesh K., Hochster, Howard S., Grothey, Axel, Yoshino, Takayuki
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2016
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4944251/
https://ncbi.nlm.nih.gov/pubmed/27412464
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2491-y
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki